Chemistry:Fluoxakalner
From HandWiki
Fluoxakalner is a Kv7.2 and Kv7.3 potassium channel opener which is under investigation for potential medical use.[1] Its EC50 for opening Kv7.2 and Kv7.3 channels has been found to be 360 nM.[1] The drug produces analgesic effects in rodents and without causing sedation or locomotor changes.[1] In addition, it did not inhibit various cardiac ion channels.[1] The chemical synthesis of fluoxakalner has been described.[1] Fluoxakalner was first described in the scientific literature by Wei Xiang and colleagues in 2026.[1] It was developed as a replacement for retigabine, which was withdrawn from the market due to toxicity.[1] Fluoxakalner avoids oxidative metabolites like retigabine's thought to be responsible for said toxicity.[1]
See also
References
 |  |
